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Objectives
At the end of this session, participants will be able to:  Describe the epidemiology of HIV and tuberculosis (TB) and their close relationship  Recognize the clinical manifestations of TB in HIV infected children and adolescents  Discuss the diagnostic work-up when suspecting TB in this group of patients  Briefly discuss the management of TB in HIV infected children and adolescents
Case
DL is 4 year old male who is a recent adoptee from an orphanage in Africa. Very little is known about his birth history. He did receive the BCG vaccine in Africa. He has an HIV test done on arrival which is positive. His viral load is 154,000 and CD4 count is 199.
He also has a PPD placed which is 19 mm and a CXR with prominent hilar and mediastinal lymphadenopathy. • TST has poor sensitivity to detect MTB infection in HIV infected children-50% or less of these children with bacteriologically confirmed TB are TST positive
• Effective contact investigation of adults with pulmonary TB particularly those with HIV co-infection is the most efficient way to identify at-risk children both HIV infected and not infected
Diagnosis Diagnosis
 IGRAs require T-cell activity therefore HIV infection as well as the degree of immune function may diminish the utility of these tests  Younger age, HIV infection, and reduced numbers of CD4 + cells also increase the rate of indeterminate IGRA results  The T SPOT ®. TB assay has been shown to perform better than both the TST and QFT in HIV infected children and adults independent of CD4 + counts
Recommendations for Testing
 All children diagnosed with TB should be tested for HIV infection  Annual TB testing is recommended for HIV infected children beginning at 3-12 months of age and annually thereafter for those who previously tested negative
Recommendations for HIV Screening in TB Clinics
 CDC recommends HIV screening for all TB patients using the 'opt-out' approach  Routine HIV testing should also be recommended for patients suspected of having TB disease, persons with LTBI and contacts to TB patients  Rapid HIV tests can be used in these settings This figure represents the steps taken to screen for TB among people living with HIV/AIDS (PLHWA) and identify those individuals who need further evaluation. The health care provider first asks the patient if they have experienced any of these symptoms: cough of any duration; fever of any duration, or night sweats more than three times a week. If the patient answers NO to ALL of these symptoms they are considered not to be a suspect for TB disease and should be considered for isoniazid preventive therapy (IPT) to prevent TB. In this study, 97% of patients with none of these symptoms were free of TB. If the patient answers YES to ANY symptom, they should be further evaluated for TB disease, usually including smear microscopy, culture, and chest x-ray. 
Treatment of TB Disease
 Empiric treatment for TB disease using DOT should be started in all HIV infected infants and children in whom the diagnosis is strongly suspected and continued until the diagnosis has been confirmed or ruled out  The total recommended treatment duration in uncomplicated pulmonary TB disease is 9 months  For extrapulmonary disease involving bones or joints, CNS or disseminated disease, the minimum treatment duration is 12 months 
Concurrent Use of ART & TB Medications
 Beyond 2 months, liver function tests should be done every 2-3 months until the end of therapy  When treatment failure is suspected change the entire drug regimen rather than a single drug alone
Concurrent Use of cART & TB Medications: Role of Rifampin
 Choice of cART regimens must consider:
 The critical role of RIF because of its bactericidal and sterilizing properties  Potent induction of the CYP3A enzyme system and pglycoprotein-mediated efflux that lowers cART drug levels, especially protease inhibitors (PIs) except Ritonavir which partially reduces this effect  Moderate reduction in NVP levels  NRTIs and Efavirenz levels are least affected
Concurrent Use of cART & TB Medications
 Rifabutin, a rifamycin-class semi-synthetic antibiotic related to rifampin, exhibits minimal CYP3A induction and has been used in place of Rifampin, data in children are limited  Rifabutin has fewer drug interactions than RIF but requires dosage adjustments for cART drugs  Combined use of integrase inhibitors and other cART drug classes with RIF have not been evaluated in children  Ongoing studies in adults suggest that dosage adjustment may be necessary with these medications as well
 CCR5 inhibitors-since these drugs are also metabolized by the cytochrome P-450 isoenzyme 3A4 would need dosage adjustments when coadministered with rifampin  Once again obtaining drug levels where available and close monitoring for toxicities is essential when administering concomitant cART and TB medications 
Risk of Recurrent Disease
 Re-infection disease should be managed the same as first-time TB  Secondary (post-treatment) prophylaxis is not recommended  However, regular TB exposure screening should continue after completion of treatment, and preventive therapy should be considered whenever repeat exposure occurs
Risk of Relapse & Recurrent Disease
 TB recurrence can represent relapse or re-infection  The relapse rate is low in children with drug susceptible TB who receive DOT and cART  Recurrence within 6 to 12 months of treatment completion should be regarded as relapse & managed the same as treatment failure  Recurrence > 6 to 12 months post treatment completion is probably re-infection disease, especially after new TB exposure or a visit to a TB endemic setting
BACK TO THE CASE DISCUSSION
He also has a PPD placed which is 19 mm and a CXR with prominent hilar and mediastinal lymphadenopathy.
